loading page

Outcome of using Intravenous Immunoglobulin (IVIG) in critically ill COVID-19 patients’: a ‎retrospective, ‏multi-centric cohort study
  • +8
  • Mohammadreza Salehi,
  • Mahdi Barkhori Mehni,
  • Mohammadmehdi Akbarian,
  • Samrand Fattah Ghazi,
  • Nasim Khajavi Rad,
  • Omid Moradi Moghaddam,
  • Saeed reza Jamali Moghaddam,
  • Masoumeh Hosseinzadeh Emam,
  • Sayed Hamidreza Abtahi,
  • Maryam Moradi,
  • Fereshteh Ghiasvand
Mohammadreza Salehi
Imam Khomeini Hospital Complex
Author Profile
Mahdi Barkhori Mehni
Tehran University of Medical Sciences School of Medicine
Author Profile
Mohammadmehdi Akbarian
Tehran University of Medical Sciences
Author Profile
Samrand Fattah Ghazi
Imam Khomeini Hospital Complex
Author Profile
Nasim Khajavi Rad
Imam Khomeini Hospital Complex
Author Profile
Omid Moradi Moghaddam
Iran University of Medical Sciences
Author Profile
Saeed reza Jamali Moghaddam
Tehran University of Medical Sciences
Author Profile
Masoumeh Hosseinzadeh Emam
Iran University of Medical Sciences
Author Profile
Sayed Hamidreza Abtahi
Imam Khomeini Hospital Complex
Author Profile
Maryam Moradi
Iran University of Medical Sciences
Author Profile
Fereshteh Ghiasvand
Tehran University of Medical Sciences

Corresponding Author:ghiasvand_62@yahoo.com

Author Profile

Abstract

Abstract Background: To access the effect of Intravenous immunoglobulin ‎‎(IVIG) in critically ill corona virus disease 2019 (COVID-19) patients. Method: In this retrospective matched cohort study, records of three tertiary centers with large number of COVID-19 admissions were evaluated and used. Based on treatment options, ‎patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of ‎low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using independent t-test and ‎One-way analysis of variance (ANOVA) to compare the ‎outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate.‎ Result: The duration of hospitalization in the IVIG group ‎were significantly longer than standard treatment (13.74 days vs. 11.10 days, p<0.05). There was not a significant difference between the two groups in ICU length of stay, number of intubated patients and duration of mechanical ventilation (P>0.05).‎ Also initial ‎outcomes in IVIG subgroups were compared separately with the standard ‎treatment group. The results indicated that only the duration of hospitalization ‎in the IVIG subgroup with medium dose is significantly longer than the standard ‎treatment group (P<0.01). Conclusion: Using IVIG is not beneficial for COVID-19 patients based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation and even mortality rate.